Should Refined Chromosomal Analysis Be Used Routinely in Acute Leukemias and Myelodysplastic Syndrome?

Publisher Website
Google Scholar
Abstract
To the Editor: In a letter to the Editor (Sept. 5 issue),1 Williams et al. suggested that chromosome analysis is emerging as a valuable tool in identifying prognostically important subgroups of patients with acute lymphoblastic leukemia. Their series included 116 patients, most of whom were studied with an improved direct marrow technique. They reported a 98 percent rate of successful analysis, and 94 percent of the patients had a chromosome defect. Our experience with 42 consecutive patients basically confirms their findings. In addition, in a consecutive series of 192 patients with acute nonlymphocytic leukemia and 81 with myelodysplastic syndrome not . . .